Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Public advisory - APO-Mometasone nasal spray: Two lots recalled due to possible risk of infection | ||||||||||
By: PR Newswire Association LLC. - 19 Feb 2024 | Back to overview list |
|||||||||
OTTAWA, ON, Feb. 19, 2024 /CNW/ - Summary
Affected products
Issue Apotex Inc. is recalling two lots of APO-Mometasone nasal spray due to possible bacterial contamination with Burkholderia cepacia complex (Bcc). Bcc is a group of bacteria that poses a low medical risk to most healthy people; however, children, those with chronic lung diseases, people who are pregnant, seniors and those with a weakened immune system may be at a higher risk of illness. APO-Mometasone nasal spray is a prescription drug used to treat seasonal and year-round nasal allergy symptoms (such as itchy, stuffy or runny nose and sneezing) in children 3-11 years old. It is also used to treat sinusitis (sinus inflammation) in adults and children 12 years of age and older, and nasal polyps in adults. The effects of Bcc vary widely, ranging from no symptoms at all to serious infections. In severe cases, Bcc can lead to bloodstream infections that may result in sepsis (a serious medical condition caused by an overwhelming immune response to an infection) and death. Bcc is often resistant to common antibiotics. People experiencing persistent or worsening symptoms, such as fevers, or facial pain or pressure, should seek medical attention. Health Canada is monitoring the company's recall and its implementation of corrective and preventative actions. Supply might be temporarily constrained as a result of this recall. You should speak to your healthcare provider about what suitable alternative treatments are available to you or your child. What you should do
Également disponible en français SOURCE Health Canada (HC) |
||||||||||
|
||||||||||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |